1. Home
  2. MEIP vs TTEC Comparison

MEIP vs TTEC Comparison

Compare MEIP & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • TTEC
  • Stock Information
  • Founded
  • MEIP 2000
  • TTEC 1982
  • Country
  • MEIP United States
  • TTEC United States
  • Employees
  • MEIP N/A
  • TTEC N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • TTEC Retail: Computer Software & Peripheral Equipment
  • Sector
  • MEIP Health Care
  • TTEC Technology
  • Exchange
  • MEIP Nasdaq
  • TTEC Nasdaq
  • Market Cap
  • MEIP 153.9M
  • TTEC 183.7M
  • IPO Year
  • MEIP 2003
  • TTEC 1996
  • Fundamental
  • Price
  • MEIP $3.00
  • TTEC $3.78
  • Analyst Decision
  • MEIP
  • TTEC Hold
  • Analyst Count
  • MEIP 0
  • TTEC 3
  • Target Price
  • MEIP N/A
  • TTEC $3.50
  • AVG Volume (30 Days)
  • MEIP 790.3K
  • TTEC 332.2K
  • Earning Date
  • MEIP 09-23-2025
  • TTEC 11-05-2025
  • Dividend Yield
  • MEIP N/A
  • TTEC N/A
  • EPS Growth
  • MEIP N/A
  • TTEC N/A
  • EPS
  • MEIP N/A
  • TTEC N/A
  • Revenue
  • MEIP N/A
  • TTEC $2,144,663,000.00
  • Revenue This Year
  • MEIP N/A
  • TTEC N/A
  • Revenue Next Year
  • MEIP N/A
  • TTEC $0.47
  • P/E Ratio
  • MEIP N/A
  • TTEC N/A
  • Revenue Growth
  • MEIP 33.76
  • TTEC N/A
  • 52 Week Low
  • MEIP $1.46
  • TTEC $2.67
  • 52 Week High
  • MEIP $9.00
  • TTEC $6.28
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 26.36
  • TTEC 46.60
  • Support Level
  • MEIP $3.85
  • TTEC $3.66
  • Resistance Level
  • MEIP $5.50
  • TTEC $3.97
  • Average True Range (ATR)
  • MEIP 0.37
  • TTEC 0.18
  • MACD
  • MEIP -0.20
  • TTEC 0.06
  • Stochastic Oscillator
  • MEIP 3.10
  • TTEC 57.78

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About TTEC TTEC Holdings Inc.

TTEC Holdings Inc provides customer engagement management tools and services. The company operates through four operating segments that are organized into two groups, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its sales are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.

Share on Social Networks: